nur für Forschungszwecke
AZD6244 (Selumetinib) MEK1/2-Inhibitor
Kat.-Nr.S1008
Chemische Struktur
Molekulargewicht: 457.68
Springe zu
Qualitätskontrolle
Charge:
Reinheit:
99.80%
99.80
Produkte, die oft zusammen verwendet werden mit AZD6244 (Selumetinib)
| Verwandte Ziele | ERK p38 MAPK Raf JNK Ras KRas S6 Kinase MAP4K TAK1 Mixed Lineage Kinase |
|---|---|
| Weitere MEK Inhibitoren | PD0325901 (Mirdametinib) U0126-EtOH PD 98059 PD184352 (CI-1040) BIX 02189 Pimasertib (AS-703026) Refametinib (RDEA119) TAK-733 AZD8330 SL-327 |
Zellkultur, Behandlung & Arbeitskonzentration
| Zelllinien | Assay-Typ | Konzentration | Inkubationszeit | Formulierung | Aktivitätsbeschreibung | PMID |
|---|---|---|---|---|---|---|
| CHP-212 | Growth inhibition assay | Inhibition of human CHP-212 cell growth in a cell viability assay, IC50 = 0.003153 μM. | SANGER | |||
| H9 | Growth inhibition assay | Inhibition of human H9 cell growth in a cell viability assay, IC50 = 0.02288 μM. | SANGER | |||
| HL-60 | Growth inhibition assay | Inhibition of human HL-60 cell growth in a cell viability assay, IC50 = 0.02459 μM. | SANGER | |||
| NOMO-1 | Growth inhibition assay | Inhibition of human NOMO-1 cell growth in a cell viability assay, IC50 = 0.03197 μM. | SANGER | |||
| DU-4475 | Growth inhibition assay | Inhibition of human DU-4475 cell growth in a cell viability assay, IC50 = 0.03367 μM. | SANGER | |||
| M14 | Growth inhibition assay | Inhibition of human M14 cell growth in a cell viability assay, IC50 = 0.03689 μM. | SANGER | |||
| HT-144 | Growth inhibition assay | Inhibition of human HT-144 cell growth in a cell viability assay, IC50 = 0.08905 μM. | SANGER | |||
| SK-N-AS | Growth inhibition assay | Inhibition of human SK-N-AS cell growth in a cell viability assay, IC50 = 0.09283 μM. | SANGER | |||
| LB2518-MEL | Growth inhibition assay | Inhibition of human LB2518-MEL cell growth in a cell viability assay, IC50 = 0.09382 μM. | SANGER | |||
| C32 | Growth inhibition assay | Inhibition of human C32 cell growth in a cell viability assay, IC50 = 0.09823 μM. | SANGER | |||
| BHT-101 | Growth inhibition assay | Inhibition of human BHT-101 cell growth in a cell viability assay, IC50 = 0.10693 μM. | SANGER | |||
| KY821 | Growth inhibition assay | Inhibition of human KY821 cell growth in a cell viability assay, IC50 = 0.10718 μM. | SANGER | |||
| CP50-MEL-B | Growth inhibition assay | Inhibition of human CP50-MEL-B cell growth in a cell viability assay, IC50 = 0.12794 μM. | SANGER | |||
| MEL-HO | Growth inhibition assay | Inhibition of human MEL-HO cell growth in a cell viability assay, IC50 = 0.13884 μM. | SANGER | |||
| EoL-1-cell | Growth inhibition assay | Inhibition of human EoL-1-cell cell growth in a cell viability assay, IC50 = 0.14476 μM. | SANGER | |||
| DOK | Growth inhibition assay | Inhibition of human DOK cell growth in a cell viability assay, IC50 = 0.14708 μM. | SANGER | |||
| SH-4 | Growth inhibition assay | Inhibition of human SH-4 cell growth in a cell viability assay, IC50 = 0.16648 μM. | SANGER | |||
| BPH-1 | Growth inhibition assay | Inhibition of human BPH-1 cell growth in a cell viability assay, IC50 = 0.18231 μM. | SANGER | |||
| HuP-T4 | Growth inhibition assay | Inhibition of human HuP-T4 cell growth in a cell viability assay, IC50 = 0.19532 μM. | SANGER | |||
| KU812 | Growth inhibition assay | Inhibition of human KU812 cell growth in a cell viability assay, IC50 = 0.21168 μM. | SANGER | |||
| A549 | Growth inhibition assay | Inhibition of human A549 cell growth in a cell viability assay, IC50 = 0.21413 μM. | SANGER | |||
| HTC-C3 | Growth inhibition assay | Inhibition of human HTC-C3 cell growth in a cell viability assay, IC50 = 0.21461 μM. | SANGER | |||
| A101D | Growth inhibition assay | Inhibition of human A101D cell growth in a cell viability assay, IC50 = 0.24033 μM. | SANGER | |||
| ONS-76 | Growth inhibition assay | Inhibition of human ONS-76 cell growth in a cell viability assay, IC50 = 0.24453 μM. | SANGER | |||
| RKO | Growth inhibition assay | Inhibition of human RKO cell growth in a cell viability assay, IC50 = 0.24838 μM. | SANGER | |||
| WM-115 | Growth inhibition assay | Inhibition of human WM-115 cell growth in a cell viability assay, IC50 = 0.26754 μM. | SANGER | |||
| HCC2998 | Growth inhibition assay | Inhibition of human HCC2998 cell growth in a cell viability assay, IC50 = 0.26907 μM. | SANGER | |||
| C2BBe1 | Growth inhibition assay | Inhibition of human C2BBe1 cell growth in a cell viability assay, IC50 = 0.27259 μM. | SANGER | |||
| RVH-421 | Growth inhibition assay | Inhibition of human RVH-421 cell growth in a cell viability assay, IC50 = 0.27939 μM. | SANGER | |||
| H-EMC-SS | Growth inhibition assay | Inhibition of human H-EMC-SS cell growth in a cell viability assay, IC50 = 0.29099 μM. | SANGER | |||
| ML-2 | Growth inhibition assay | Inhibition of human ML-2 cell growth in a cell viability assay, IC50 = 0.29363 μM. | SANGER | |||
| SW620 | Growth inhibition assay | Inhibition of human SW620 cell growth in a cell viability assay, IC50 = 0.3022 μM. | SANGER | |||
| UACC-257 | Growth inhibition assay | Inhibition of human UACC-257 cell growth in a cell viability assay, IC50 = 0.32184 μM. | SANGER | |||
| AsPC-1 | Growth inhibition assay | Inhibition of human AsPC-1 cell growth in a cell viability assay, IC50 = 0.32439 μM. | SANGER | |||
| CAL-39 | Growth inhibition assay | Inhibition of human CAL-39 cell growth in a cell viability assay, IC50 = 0.33226 μM. | SANGER | |||
| COLO-679 | Growth inhibition assay | Inhibition of human COLO-679 cell growth in a cell viability assay, IC50 = 0.34119 μM. | SANGER | |||
| NCI-H747 | Growth inhibition assay | Inhibition of human NCI-H747 cell growth in a cell viability assay, IC50 = 0.35098 μM. | SANGER | |||
| NCI-H1437 | Growth inhibition assay | Inhibition of human NCI-H1437 cell growth in a cell viability assay, IC50 = 0.35285 μM. | SANGER | |||
| PSN1 | Growth inhibition assay | Inhibition of human PSN1 cell growth in a cell viability assay, IC50 = 0.36609 μM. | SANGER | |||
| NKM-1 | Growth inhibition assay | Inhibition of human NKM-1 cell growth in a cell viability assay, IC50 = 0.3858 μM. | SANGER | |||
| MZ2-MEL | Growth inhibition assay | Inhibition of human MZ2-MEL cell growth in a cell viability assay, IC50 = 0.39437 μM. | SANGER | |||
| SK-MEL-2 | Growth inhibition assay | Inhibition of human SK-MEL-2 cell growth in a cell viability assay, IC50 = 0.40506 μM. | SANGER | |||
| LAMA-84 | Growth inhibition assay | Inhibition of human LAMA-84 cell growth in a cell viability assay, IC50 = 0.45622 μM. | SANGER | |||
| U-266 | Growth inhibition assay | Inhibition of human U-266 cell growth in a cell viability assay, IC50 = 0.48774 μM. | SANGER | |||
| RCM-1 | Growth inhibition assay | Inhibition of human RCM-1 cell growth in a cell viability assay, IC50 = 0.49385 μM. | SANGER | |||
| EM-2 | Growth inhibition assay | Inhibition of human EM-2 cell growth in a cell viability assay, IC50 = 0.51175 μM. | SANGER | |||
| Mewo | Growth inhibition assay | Inhibition of human Mewo cell growth in a cell viability assay, IC50 = 0.52101 μM. | SANGER | |||
| COLO-741 | Growth inhibition assay | Inhibition of human COLO-741 cell growth in a cell viability assay, IC50 = 0.53119 μM. | SANGER | |||
| ACN | Growth inhibition assay | Inhibition of human ACN cell growth in a cell viability assay, IC50 = 0.5669 μM. | SANGER | |||
| MV-4-11 | Growth inhibition assay | Inhibition of human MV-4-11 cell growth in a cell viability assay, IC50 = 0.57543 μM. | SANGER | |||
| SW780 | Growth inhibition assay | Inhibition of human SW780 cell growth in a cell viability assay, IC50 = 0.66634 μM. | SANGER | |||
| JVM-3 | Growth inhibition assay | Inhibition of human JVM-3 cell growth in a cell viability assay, IC50 = 0.7006 μM. | SANGER | |||
| RPMI-8226 | Growth inhibition assay | Inhibition of human RPMI-8226 cell growth in a cell viability assay, IC50 = 0.74 μM. | SANGER | |||
| HO-1-N-1 | Growth inhibition assay | Inhibition of human HO-1-N-1 cell growth in a cell viability assay, IC50 = 0.74052 μM. | SANGER | |||
| BV-173 | Growth inhibition assay | Inhibition of human BV-173 cell growth in a cell viability assay, IC50 = 0.74802 μM. | SANGER | |||
| NCI-H2291 | Growth inhibition assay | Inhibition of human NCI-H2291 cell growth in a cell viability assay, IC50 = 0.76173 μM. | SANGER | |||
| SK-MEL-30 | Growth inhibition assay | Inhibition of human SK-MEL-30 cell growth in a cell viability assay, IC50 = 0.78171 μM. | SANGER | |||
| LB2241-RCC | Growth inhibition assay | Inhibition of human LB2241-RCC cell growth in a cell viability assay, IC50 = 0.78991 μM. | SANGER | |||
| LOXIMVI | Growth inhibition assay | Inhibition of human LOXIMVI cell growth in a cell viability assay, IC50 = 0.85854 μM. | SANGER | |||
| HT-29 | Growth inhibition assay | Inhibition of human HT-29 cell growth in a cell viability assay, IC50 = 0.87319 μM. | SANGER | |||
| KG-1 | Growth inhibition assay | Inhibition of human KG-1 cell growth in a cell viability assay, IC50 = 0.89547 μM. | SANGER | |||
| SW954 | Growth inhibition assay | Inhibition of human SW954 cell growth in a cell viability assay, IC50 = 0.89645 μM. | SANGER | |||
| MIA-PaCa-2 | Growth inhibition assay | Inhibition of human MIA-PaCa-2 cell growth in a cell viability assay, IC50 = 0.89768 μM. | SANGER | |||
| HCE-T | Growth inhibition assay | Inhibition of human HCE-T cell growth in a cell viability assay, IC50 = 0.97131 μM. | SANGER | |||
| HN | Growth inhibition assay | Inhibition of human HN cell growth in a cell viability assay, IC50 = 1.00257 μM. | SANGER | |||
| LCLC-97TM1 | Growth inhibition assay | Inhibition of human LCLC-97TM1 cell growth in a cell viability assay, IC50 = 1.03191 μM. | SANGER | |||
| NB69 | Growth inhibition assay | Inhibition of human NB69 cell growth in a cell viability assay, IC50 = 1.0539 μM. | SANGER | |||
| LoVo | Growth inhibition assay | Inhibition of human LoVo cell growth in a cell viability assay, IC50 = 1.06231 μM. | SANGER | |||
| HCT-116 | Growth inhibition assay | Inhibition of human HCT-116 cell growth in a cell viability assay, IC50 = 1.06431 μM. | SANGER | |||
| AGS | Growth inhibition assay | Inhibition of human AGS cell growth in a cell viability assay, IC50 = 1.11831 μM. | SANGER | |||
| NCI-H292 | Growth inhibition assay | Inhibition of human NCI-H292 cell growth in a cell viability assay, IC50 = 1.1199 μM. | SANGER | |||
| P12-ICHIKAWA | Growth inhibition assay | Inhibition of human P12-ICHIKAWA cell growth in a cell viability assay, IC50 = 1.15899 μM. | SANGER | |||
| D-263MG | Growth inhibition assay | Inhibition of human D-263MG cell growth in a cell viability assay, IC50 = 1.18094 μM. | SANGER | |||
| COLO-792 | Growth inhibition assay | Inhibition of human COLO-792 cell growth in a cell viability assay, IC50 = 1.1863 μM. | SANGER | |||
| HSC-3 | Growth inhibition assay | Inhibition of human HSC-3 cell growth in a cell viability assay, IC50 = 1.18823 μM. | SANGER | |||
| NUGC-3 | Growth inhibition assay | Inhibition of human NUGC-3 cell growth in a cell viability assay, IC50 = 1.20379 μM. | SANGER | |||
| SW872 | Growth inhibition assay | Inhibition of human SW872 cell growth in a cell viability assay, IC50 = 1.26855 μM. | SANGER | |||
| HuCCT1 | Growth inhibition assay | Inhibition of human HuCCT1 cell growth in a cell viability assay, IC50 = 1.2996 μM. | SANGER | |||
| QIMR-WIL | Growth inhibition assay | Inhibition of human QIMR-WIL cell growth in a cell viability assay, IC50 = 1.34384 μM. | SANGER | |||
| NCI-H2087 | Growth inhibition assay | Inhibition of human NCI-H2087 cell growth in a cell viability assay, IC50 = 1.3751 μM. | SANGER | |||
| LS-513 | Growth inhibition assay | Inhibition of human LS-513 cell growth in a cell viability assay, IC50 = 1.42191 μM. | SANGER | |||
| CAL-54 | Growth inhibition assay | Inhibition of human CAL-54 cell growth in a cell viability assay, IC50 = 1.49314 μM. | SANGER | |||
| A204 | Growth inhibition assay | Inhibition of human A204 cell growth in a cell viability assay, IC50 = 1.51667 μM. | SANGER | |||
| CAL-62 | Growth inhibition assay | Inhibition of human CAL-62 cell growth in a cell viability assay, IC50 = 1.52292 μM. | SANGER | |||
| CAL-33 | Growth inhibition assay | Inhibition of human CAL-33 cell growth in a cell viability assay, IC50 = 1.54694 μM. | SANGER | |||
| COLO-678 | Growth inhibition assay | Inhibition of human COLO-678 cell growth in a cell viability assay, IC50 = 1.62382 μM. | SANGER | |||
| MEG-01 | Growth inhibition assay | Inhibition of human MEG-01 cell growth in a cell viability assay, IC50 = 1.62959 μM. | SANGER | |||
| HAL-01 | Growth inhibition assay | Inhibition of human HAL-01 cell growth in a cell viability assay, IC50 = 1.6957 μM. | SANGER | |||
| OAW-28 | Growth inhibition assay | Inhibition of human OAW-28 cell growth in a cell viability assay, IC50 = 1.74397 μM. | SANGER | |||
| NCI-SNU-1 | Growth inhibition assay | Inhibition of human NCI-SNU-1 cell growth in a cell viability assay, IC50 = 1.77243 μM. | SANGER | |||
| BHY | Growth inhibition assay | Inhibition of human BHY cell growth in a cell viability assay, IC50 = 1.81034 μM. | SANGER | |||
| EGI-1 | Growth inhibition assay | Inhibition of human EGI-1 cell growth in a cell viability assay, IC50 = 1.8282 μM. | SANGER | |||
| BB65-RCC | Growth inhibition assay | Inhibition of human BB65-RCC cell growth in a cell viability assay, IC50 = 1.83855 μM. | SANGER | |||
| GAK | Growth inhibition assay | Inhibition of human GAK cell growth in a cell viability assay, IC50 = 1.90475 μM. | SANGER | |||
| SK-MEL-3 | Growth inhibition assay | Inhibition of human SK-MEL-3 cell growth in a cell viability assay, IC50 = 1.95077 μM. | SANGER | |||
| KARPAS-45 | Growth inhibition assay | Inhibition of human KARPAS-45 cell growth in a cell viability assay, IC50 = 2.08248 μM. | SANGER | |||
| BCPAP | Growth inhibition assay | Inhibition of human BCPAP cell growth in a cell viability assay, IC50 = 2.1274 μM. | SANGER | |||
| RT-112 | Growth inhibition assay | Inhibition of human RT-112 cell growth in a cell viability assay, IC50 = 2.26046 μM. | SANGER | |||
| SK-HEP-1 | Growth inhibition assay | Inhibition of human SK-HEP-1 cell growth in a cell viability assay, IC50 = 2.29048 μM. | SANGER | |||
| Ca9-22 | Growth inhibition assay | Inhibition of human Ca9-22 cell growth in a cell viability assay, IC50 = 2.37667 μM. | SANGER | |||
| OS-RC-2 | Growth inhibition assay | Inhibition of human OS-RC-2 cell growth in a cell viability assay, IC50 = 2.40337 μM. | SANGER | |||
| BFTC-905 | Growth inhibition assay | Inhibition of human BFTC-905 cell growth in a cell viability assay, IC50 = 2.42312 μM. | SANGER | |||
| HT-1080 | Growth inhibition assay | Inhibition of human HT-1080 cell growth in a cell viability assay, IC50 = 2.4301 μM. | SANGER | |||
| HCC2218 | Growth inhibition assay | Inhibition of human HCC2218 cell growth in a cell viability assay, IC50 = 2.48487 μM. | SANGER | |||
| KM12 | Growth inhibition assay | Inhibition of human KM12 cell growth in a cell viability assay, IC50 = 2.53961 μM. | SANGER | |||
| NB5 | Growth inhibition assay | Inhibition of human NB5 cell growth in a cell viability assay, IC50 = 2.56641 μM. | SANGER | |||
| BB30-HNC | Growth inhibition assay | Inhibition of human BB30-HNC cell growth in a cell viability assay, IC50 = 2.71293 μM. | SANGER | |||
| NCI-H460 | Growth inhibition assay | Inhibition of human NCI-H460 cell growth in a cell viability assay, IC50 = 2.80274 μM. | SANGER | |||
| LAN-6 | Growth inhibition assay | Inhibition of human LAN-6 cell growth in a cell viability assay, IC50 = 2.82867 μM. | SANGER | |||
| EW-3 | Growth inhibition assay | Inhibition of human EW-3 cell growth in a cell viability assay, IC50 = 2.92505 μM. | SANGER | |||
| CAL-27 | Growth inhibition assay | Inhibition of human CAL-27 cell growth in a cell viability assay, IC50 = 3.06118 μM. | SANGER | |||
| COR-L105 | Growth inhibition assay | Inhibition of human COR-L105 cell growth in a cell viability assay, IC50 = 3.13462 μM. | SANGER | |||
| EFO-21 | Growth inhibition assay | Inhibition of human EFO-21 cell growth in a cell viability assay, IC50 = 3.19226 μM. | SANGER | |||
| MZ1-PC | Growth inhibition assay | Inhibition of human MZ1-PC cell growth in a cell viability assay, IC50 = 3.31605 μM. | SANGER | |||
| EFO-27 | Growth inhibition assay | Inhibition of human EFO-27 cell growth in a cell viability assay, IC50 = 3.32612 μM. | SANGER | |||
| HPAF-II | Growth inhibition assay | Inhibition of human HPAF-II cell growth in a cell viability assay, IC50 = 3.33729 μM. | SANGER | |||
| KU-19-19 | Growth inhibition assay | Inhibition of human KU-19-19 cell growth in a cell viability assay, IC50 = 3.41951 μM. | SANGER | |||
| NCI-SNU-5 | Growth inhibition assay | Inhibition of human NCI-SNU-5 cell growth in a cell viability assay, IC50 = 3.61449 μM. | SANGER | |||
| LS-123 | Growth inhibition assay | Inhibition of human LS-123 cell growth in a cell viability assay, IC50 = 3.61831 μM. | SANGER | |||
| 769-P | Growth inhibition assay | Inhibition of human 769-P cell growth in a cell viability assay, IC50 = 3.7426 μM. | SANGER | |||
| SJSA-1 | Growth inhibition assay | Inhibition of human SJSA-1 cell growth in a cell viability assay, IC50 = 3.78146 μM. | SANGER | |||
| SK-LU-1 | Growth inhibition assay | Inhibition of human SK-LU-1 cell growth in a cell viability assay, IC50 = 3.86231 μM. | SANGER | |||
| A3-KAW | Growth inhibition assay | Inhibition of human A3-KAW cell growth in a cell viability assay, IC50 = 3.91055 μM. | SANGER | |||
| LB996-RCC | Growth inhibition assay | Inhibition of human LB996-RCC cell growth in a cell viability assay, IC50 = 3.95043 μM. | SANGER | |||
| SN12C | Growth inhibition assay | Inhibition of human SN12C cell growth in a cell viability assay, IC50 = 3.95573 μM. | SANGER | |||
| COR-L23 | Growth inhibition assay | Inhibition of human COR-L23 cell growth in a cell viability assay, IC50 = 3.95669 μM. | SANGER | |||
| VM-CUB-1 | Growth inhibition assay | Inhibition of human VM-CUB-1 cell growth in a cell viability assay, IC50 = 3.96931 μM. | SANGER | |||
| RXF393 | Growth inhibition assay | Inhibition of human RXF393 cell growth in a cell viability assay, IC50 = 4.01591 μM. | SANGER | |||
| MOLT-13 | Growth inhibition assay | Inhibition of human MOLT-13 cell growth in a cell viability assay, IC50 = 4.03419 μM. | SANGER | |||
| GCT | Growth inhibition assay | Inhibition of human GCT cell growth in a cell viability assay, IC50 = 4.10442 μM. | SANGER | |||
| SW1990 | Growth inhibition assay | Inhibition of human SW1990 cell growth in a cell viability assay, IC50 = 4.16622 μM. | SANGER | |||
| RD | Growth inhibition assay | Inhibition of human RD cell growth in a cell viability assay, IC50 = 4.19138 μM. | SANGER | |||
| HOP-92 | Growth inhibition assay | Inhibition of human HOP-92 cell growth in a cell viability assay, IC50 = 4.20093 μM. | SANGER | |||
| ME-180 | Growth inhibition assay | Inhibition of human ME-180 cell growth in a cell viability assay, IC50 = 4.25859 μM. | SANGER | |||
| MZ7-mel | Growth inhibition assay | Inhibition of human MZ7-mel cell growth in a cell viability assay, IC50 = 4.45265 μM. | SANGER | |||
| CAKI-1 | Growth inhibition assay | Inhibition of human CAKI-1 cell growth in a cell viability assay, IC50 = 4.46057 μM. | SANGER | |||
| YKG-1 | Growth inhibition assay | Inhibition of human YKG-1 cell growth in a cell viability assay, IC50 = 4.53421 μM. | SANGER | |||
| PANC-03-27 | Growth inhibition assay | Inhibition of human PANC-03-27 cell growth in a cell viability assay, IC50 = 4.53929 μM. | SANGER | |||
| A4-Fuk | Growth inhibition assay | Inhibition of human A4-Fuk cell growth in a cell viability assay, IC50 = 4.54202 μM. | SANGER | |||
| NCI-H441 | Growth inhibition assay | Inhibition of human NCI-H441 cell growth in a cell viability assay, IC50 = 4.56342 μM. | SANGER | |||
| BxPC-3 | Growth inhibition assay | Inhibition of human BxPC-3 cell growth in a cell viability assay, IC50 = 4.65976 μM. | SANGER | |||
| ES3 | Growth inhibition assay | Inhibition of human ES3 cell growth in a cell viability assay, IC50 = 4.69173 μM. | SANGER | |||
| GP5d | Growth inhibition assay | Inhibition of human GP5d cell growth in a cell viability assay, IC50 = 4.78553 μM. | SANGER | |||
| CAL-85-1 | Growth inhibition assay | Inhibition of human CAL-85-1 cell growth in a cell viability assay, IC50 = 4.7942 μM. | SANGER | |||
| EPLC-272H | Growth inhibition assay | Inhibition of human EPLC-272H cell growth in a cell viability assay, IC50 = 4.81698 μM. | SANGER | |||
| HuP-T3 | Growth inhibition assay | Inhibition of human HuP-T3 cell growth in a cell viability assay, IC50 = 4.82408 μM. | SANGER | |||
| SW1710 | Growth inhibition assay | Inhibition of human SW1710 cell growth in a cell viability assay, IC50 = 5.03549 μM. | SANGER | |||
| TE-8 | Growth inhibition assay | Inhibition of human TE-8 cell growth in a cell viability assay, IC50 = 5.06911 μM. | SANGER | |||
| TE-12 | Growth inhibition assay | Inhibition of human TE-12 cell growth in a cell viability assay, IC50 = 5.13703 μM. | SANGER | |||
| NCI-H1573 | Growth inhibition assay | Inhibition of human NCI-H1573 cell growth in a cell viability assay, IC50 = 5.27238 μM. | SANGER | |||
| SW1417 | Growth inhibition assay | Inhibition of human SW1417 cell growth in a cell viability assay, IC50 = 5.27398 μM. | SANGER | |||
| CHL-1 | Growth inhibition assay | Inhibition of human CHL-1 cell growth in a cell viability assay, IC50 = 5.3199 μM. | SANGER | |||
| Calu-6 | Growth inhibition assay | Inhibition of human Calu-6 cell growth in a cell viability assay, IC50 = 5.42927 μM. | SANGER | |||
| MDA-MB-231 | Growth inhibition assay | Inhibition of human MDA-MB-231 cell growth in a cell viability assay, IC50 = 5.56523 μM. | SANGER | |||
| SCC-25 | Growth inhibition assay | Inhibition of human SCC-25 cell growth in a cell viability assay, IC50 = 5.97121 μM. | SANGER | |||
| 639-V | Growth inhibition assay | Inhibition of human 639-V cell growth in a cell viability assay, IC50 = 6.12933 μM. | SANGER | |||
| D-502MG | Growth inhibition assay | Inhibition of human D-502MG cell growth in a cell viability assay, IC50 = 6.17659 μM. | SANGER | |||
| PANC-10-05 | Growth inhibition assay | Inhibition of human PANC-10-05 cell growth in a cell viability assay, IC50 = 6.20181 μM. | SANGER | |||
| Ramos-2G6-4C10 | Growth inhibition assay | Inhibition of human Ramos-2G6-4C10 cell growth in a cell viability assay, IC50 = 6.27094 μM. | SANGER | |||
| NB10 | Growth inhibition assay | Inhibition of human NB10 cell growth in a cell viability assay, IC50 = 6.32533 μM. | SANGER | |||
| MSTO-211H | Growth inhibition assay | Inhibition of human MSTO-211H cell growth in a cell viability assay, IC50 = 6.4008 μM. | SANGER | |||
| NCI-H1651 | Growth inhibition assay | Inhibition of human NCI-H1651 cell growth in a cell viability assay, IC50 = 6.65328 μM. | SANGER | |||
| 697 | Growth inhibition assay | Inhibition of human 697 cell growth in a cell viability assay, IC50 = 6.67397 μM. | SANGER | |||
| HCC70 | Growth inhibition assay | Inhibition of human HCC70 cell growth in a cell viability assay, IC50 = 6.68865 μM. | SANGER | |||
| SW1116 | Growth inhibition assay | Inhibition of human SW1116 cell growth in a cell viability assay, IC50 = 6.81297 μM. | SANGER | |||
| SK-MES-1 | Growth inhibition assay | Inhibition of human SK-MES-1 cell growth in a cell viability assay, IC50 = 6.8488 μM. | SANGER | |||
| GCIY | Growth inhibition assay | Inhibition of human GCIY cell growth in a cell viability assay, IC50 = 6.91962 μM. | SANGER | |||
| GMS-10 | Growth inhibition assay | Inhibition of human GMS-10 cell growth in a cell viability assay, IC50 = 7.07755 μM. | SANGER | |||
| NCI-H1092 | Growth inhibition assay | Inhibition of human NCI-H1092 cell growth in a cell viability assay, IC50 = 7.15334 μM. | SANGER | |||
| CFPAC-1 | Growth inhibition assay | Inhibition of human CFPAC-1 cell growth in a cell viability assay, IC50 = 7.22101 μM. | SANGER | |||
| TK10 | Growth inhibition assay | Inhibition of human TK10 cell growth in a cell viability assay, IC50 = 7.35587 μM. | SANGER | |||
| FADU | Growth inhibition assay | Inhibition of human FADU cell growth in a cell viability assay, IC50 = 7.5093 μM. | SANGER | |||
| 8305C | Growth inhibition assay | Inhibition of human 8305C cell growth in a cell viability assay, IC50 = 7.85355 μM. | SANGER | |||
| DK-MG | Growth inhibition assay | Inhibition of human DK-MG cell growth in a cell viability assay, IC50 = 7.94937 μM. | SANGER | |||
| BFTC-909 | Growth inhibition assay | Inhibition of human BFTC-909 cell growth in a cell viability assay, IC50 = 7.97836 μM. | SANGER | |||
| IGR-1 | Growth inhibition assay | Inhibition of human IGR-1 cell growth in a cell viability assay, IC50 = 8.18051 μM. | SANGER | |||
| MDA-MB-361 | Growth inhibition assay | Inhibition of human MDA-MB-361 cell growth in a cell viability assay, IC50 = 8.1824 μM. | SANGER | |||
| KYSE-150 | Growth inhibition assay | Inhibition of human KYSE-150 cell growth in a cell viability assay, IC50 = 8.21937 μM. | SANGER | |||
| DB | Growth inhibition assay | Inhibition of human DB cell growth in a cell viability assay, IC50 = 8.36905 μM. | SANGER | |||
| NH-12 | Growth inhibition assay | Inhibition of human NH-12 cell growth in a cell viability assay, IC50 = 8.42736 μM. | SANGER | |||
| CTV-1 | Growth inhibition assay | Inhibition of human CTV-1 cell growth in a cell viability assay, IC50 = 8.43337 μM. | SANGER | |||
| A498 | Growth inhibition assay | Inhibition of human A498 cell growth in a cell viability assay, IC50 = 8.78475 μM. | SANGER | |||
| LS-1034 | Growth inhibition assay | Inhibition of human LS-1034 cell growth in a cell viability assay, IC50 = 8.96464 μM. | SANGER | |||
| FTC-133 | Growth inhibition assay | Inhibition of human FTC-133 cell growth in a cell viability assay, IC50 = 8.98459 μM. | SANGER | |||
| TGBC11TKB | Growth inhibition assay | Inhibition of human TGBC11TKB cell growth in a cell viability assay, IC50 = 9.10836 μM. | SANGER | |||
| SK-MEL-1 | Growth inhibition assay | Inhibition of human SK-MEL-1 cell growth in a cell viability assay, IC50 = 9.19136 μM. | SANGER | |||
| RPMI-7951 | Growth inhibition assay | Inhibition of human RPMI-7951 cell growth in a cell viability assay, IC50 = 9.25201 μM. | SANGER | |||
| GT3TKB | Growth inhibition assay | Inhibition of human GT3TKB cell growth in a cell viability assay, IC50 = 9.37403 μM. | SANGER | |||
| SW962 | Growth inhibition assay | Inhibition of human SW962 cell growth in a cell viability assay, IC50 = 9.52325 μM. | SANGER | |||
| T-24 | Growth inhibition assay | Inhibition of human T-24 cell growth in a cell viability assay, IC50 = 9.65807 μM. | SANGER | |||
| DBTRG-05MG | Growth inhibition assay | Inhibition of human DBTRG-05MG cell growth in a cell viability assay, IC50 = 9.75666 μM. | SANGER | |||
| G-401 | Growth inhibition assay | Inhibition of human G-401 cell growth in a cell viability assay, IC50 = 10.0739 μM. | SANGER | |||
| RS4-11 | Growth inhibition assay | Inhibition of human RS4-11 cell growth in a cell viability assay, IC50 = 10.2791 μM. | SANGER | |||
| KGN | Growth inhibition assay | Inhibition of human KGN cell growth in a cell viability assay, IC50 = 10.4046 μM. | SANGER | |||
| 786-0 | Growth inhibition assay | Inhibition of human 786-0 cell growth in a cell viability assay, IC50 = 10.4166 μM. | SANGER | |||
| EW-18 | Growth inhibition assay | Inhibition of human EW-18 cell growth in a cell viability assay, IC50 = 10.4366 μM. | SANGER | |||
| DEL | Growth inhibition assay | Inhibition of human DEL cell growth in a cell viability assay, IC50 = 10.545 μM. | SANGER | |||
| HuH-7 | Growth inhibition assay | Inhibition of human HuH-7 cell growth in a cell viability assay, IC50 = 10.5705 μM. | SANGER | |||
| MG-63 | Growth inhibition assay | Inhibition of human MG-63 cell growth in a cell viability assay, IC50 = 10.7333 μM. | SANGER | |||
| A253 | Growth inhibition assay | Inhibition of human A253 cell growth in a cell viability assay, IC50 = 10.7902 μM. | SANGER | |||
| TGW | Growth inhibition assay | Inhibition of human TGW cell growth in a cell viability assay, IC50 = 10.7937 μM. | SANGER | |||
| HH | Growth inhibition assay | Inhibition of human HH cell growth in a cell viability assay, IC50 = 10.8062 μM. | SANGER | |||
| LS-411N | Growth inhibition assay | Inhibition of human LS-411N cell growth in a cell viability assay, IC50 = 10.8244 μM. | SANGER | |||
| NCI-H2347 | Growth inhibition assay | Inhibition of human NCI-H2347 cell growth in a cell viability assay, IC50 = 10.8437 μM. | SANGER | |||
| LU-65 | Growth inhibition assay | Inhibition of human LU-65 cell growth in a cell viability assay, IC50 = 10.9226 μM. | SANGER | |||
| TE-11 | Growth inhibition assay | Inhibition of human TE-11 cell growth in a cell viability assay, IC50 = 11.025 μM. | SANGER | |||
| SBC-1 | Growth inhibition assay | Inhibition of human SBC-1 cell growth in a cell viability assay, IC50 = 11.1032 μM. | SANGER | |||
| TGBC24TKB | Growth inhibition assay | Inhibition of human TGBC24TKB cell growth in a cell viability assay, IC50 = 11.118 μM. | SANGER | |||
| ECC10 | Growth inhibition assay | Inhibition of human ECC10 cell growth in a cell viability assay, IC50 = 11.2283 μM. | SANGER | |||
| GR-ST | Growth inhibition assay | Inhibition of human GR-ST cell growth in a cell viability assay, IC50 = 11.268 μM. | SANGER | |||
| NCI-H720 | Growth inhibition assay | Inhibition of human NCI-H720 cell growth in a cell viability assay, IC50 = 11.3977 μM. | SANGER | |||
| VA-ES-BJ | Growth inhibition assay | Inhibition of human VA-ES-BJ cell growth in a cell viability assay, IC50 = 11.5513 μM. | SANGER | |||
| MOLT-16 | Growth inhibition assay | Inhibition of human MOLT-16 cell growth in a cell viability assay, IC50 = 12.1161 μM. | SANGER | |||
| KYSE-140 | Growth inhibition assay | Inhibition of human KYSE-140 cell growth in a cell viability assay, IC50 = 12.1596 μM. | SANGER | |||
| SCC-4 | Growth inhibition assay | Inhibition of human SCC-4 cell growth in a cell viability assay, IC50 = 12.24 μM. | SANGER | |||
| NCI-H1155 | Growth inhibition assay | Inhibition of human NCI-H1155 cell growth in a cell viability assay, IC50 = 12.3017 μM. | SANGER | |||
| OCUB-M | Growth inhibition assay | Inhibition of human OCUB-M cell growth in a cell viability assay, IC50 = 12.3189 μM. | SANGER | |||
| MN-60 | Growth inhibition assay | Inhibition of human MN-60 cell growth in a cell viability assay, IC50 = 12.3732 μM. | SANGER | |||
| RO82-W-1 | Growth inhibition assay | Inhibition of human RO82-W-1 cell growth in a cell viability assay, IC50 = 12.3879 μM. | SANGER | |||
| KOSC-2 | Growth inhibition assay | Inhibition of human KOSC-2 cell growth in a cell viability assay, IC50 = 12.5508 μM. | SANGER | |||
| L-363 | Growth inhibition assay | Inhibition of human L-363 cell growth in a cell viability assay, IC50 = 12.5925 μM. | SANGER | |||
| NCI-H661 | Growth inhibition assay | Inhibition of human NCI-H661 cell growth in a cell viability assay, IC50 = 12.8587 μM. | SANGER | |||
| KYSE-450 | Growth inhibition assay | Inhibition of human KYSE-450 cell growth in a cell viability assay, IC50 = 13.0396 μM. | SANGER | |||
| TI-73 | Growth inhibition assay | Inhibition of human TI-73 cell growth in a cell viability assay, IC50 = 13.044 μM. | SANGER | |||
| KNS-81-FD | Growth inhibition assay | Inhibition of human KNS-81-FD cell growth in a cell viability assay, IC50 = 13.0748 μM. | SANGER | |||
| HCC1954 | Growth inhibition assay | Inhibition of human HCC1954 cell growth in a cell viability assay, IC50 = 13.2783 μM. | SANGER | |||
| A427 | Growth inhibition assay | Inhibition of human A427 cell growth in a cell viability assay, IC50 = 13.6689 μM. | SANGER | |||
| MOLT-4 | Growth inhibition assay | Inhibition of human MOLT-4 cell growth in a cell viability assay, IC50 = 13.8531 μM. | SANGER | |||
| U-118-MG | Growth inhibition assay | Inhibition of human U-118-MG cell growth in a cell viability assay, IC50 = 13.8702 μM. | SANGER | |||
| SF126 | Growth inhibition assay | Inhibition of human SF126 cell growth in a cell viability assay, IC50 = 13.9165 μM. | SANGER | |||
| SF539 | Growth inhibition assay | Inhibition of human SF539 cell growth in a cell viability assay, IC50 = 13.9474 μM. | SANGER | |||
| Daoy | Growth inhibition assay | Inhibition of human Daoy cell growth in a cell viability assay, IC50 = 14.4979 μM. | SANGER | |||
| DoTc2-4510 | Growth inhibition assay | Inhibition of human DoTc2-4510 cell growth in a cell viability assay, IC50 = 14.5175 μM. | SANGER | |||
| TYK-nu | Growth inhibition assay | Inhibition of human TYK-nu cell growth in a cell viability assay, IC50 = 14.56 μM. | SANGER | |||
| CGTH-W-1 | Growth inhibition assay | Inhibition of human CGTH-W-1 cell growth in a cell viability assay, IC50 = 14.8483 μM. | SANGER | |||
| HuO9 | Growth inhibition assay | Inhibition of human HuO9 cell growth in a cell viability assay, IC50 = 15.063 μM. | SANGER | |||
| EW-16 | Growth inhibition assay | Inhibition of human EW-16 cell growth in a cell viability assay, IC50 = 15.0949 μM. | SANGER | |||
| NCI-H630 | Growth inhibition assay | Inhibition of human NCI-H630 cell growth in a cell viability assay, IC50 = 15.1613 μM. | SANGER | |||
| CAL-12T | Growth inhibition assay | Inhibition of human CAL-12T cell growth in a cell viability assay, IC50 = 15.331 μM. | SANGER | |||
| TE-5 | Growth inhibition assay | Inhibition of human TE-5 cell growth in a cell viability assay, IC50 = 15.6133 μM. | SANGER | |||
| U251 | Growth inhibition assay | Inhibition of human U251 cell growth in a cell viability assay, IC50 = 15.7383 μM. | SANGER | |||
| BB49-HNC | Growth inhibition assay | Inhibition of human BB49-HNC cell growth in a cell viability assay, IC50 = 16.506 μM. | SANGER | |||
| OCI-AML2 | Growth inhibition assay | Inhibition of human OCI-AML2 cell growth in a cell viability assay, IC50 = 16.665 μM. | SANGER | |||
| KINGS-1 | Growth inhibition assay | Inhibition of human KINGS-1 cell growth in a cell viability assay, IC50 = 16.6918 μM. | SANGER | |||
| D-566MG | Growth inhibition assay | Inhibition of human D-566MG cell growth in a cell viability assay, IC50 = 16.7262 μM. | SANGER | |||
| P30-OHK | Growth inhibition assay | Inhibition of human P30-OHK cell growth in a cell viability assay, IC50 = 16.9068 μM. | SANGER | |||
| GAMG | Growth inhibition assay | Inhibition of human GAMG cell growth in a cell viability assay, IC50 = 16.9243 μM. | SANGER | |||
| HCC1419 | Growth inhibition assay | Inhibition of human HCC1419 cell growth in a cell viability assay, IC50 = 17.6139 μM. | SANGER | |||
| SNU-C2B | Growth inhibition assay | Inhibition of human SNU-C2B cell growth in a cell viability assay, IC50 = 17.7377 μM. | SANGER | |||
| MHH-NB-11 | Growth inhibition assay | Inhibition of human MHH-NB-11 cell growth in a cell viability assay, IC50 = 18.1383 μM. | SANGER | |||
| COLO-684 | Growth inhibition assay | Inhibition of human COLO-684 cell growth in a cell viability assay, IC50 = 18.2383 μM. | SANGER | |||
| OC-314 | Growth inhibition assay | Inhibition of human OC-314 cell growth in a cell viability assay, IC50 = 18.358 μM. | SANGER | |||
| Becker | Growth inhibition assay | Inhibition of human Becker cell growth in a cell viability assay, IC50 = 18.4623 μM. | SANGER | |||
| NCI-H1623 | Growth inhibition assay | Inhibition of human NCI-H1623 cell growth in a cell viability assay, IC50 = 18.6368 μM. | SANGER | |||
| IGROV-1 | Growth inhibition assay | Inhibition of human IGROV-1 cell growth in a cell viability assay, IC50 = 18.6559 μM. | SANGER | |||
| HSC-2 | Growth inhibition assay | Inhibition of human HSC-2 cell growth in a cell viability assay, IC50 = 18.9577 μM. | SANGER | |||
| RMG-I | Growth inhibition assay | Inhibition of human RMG-I cell growth in a cell viability assay, IC50 = 19.1338 μM. | SANGER | |||
| CAL-120 | Growth inhibition assay | Inhibition of human CAL-120 cell growth in a cell viability assay, IC50 = 19.2354 μM. | SANGER | |||
| GB-1 | Growth inhibition assay | Inhibition of human GB-1 cell growth in a cell viability assay, IC50 = 19.7444 μM. | SANGER | |||
| LU-139 | Growth inhibition assay | Inhibition of human LU-139 cell growth in a cell viability assay, IC50 = 20.1816 μM. | SANGER | |||
| HT-1376 | Growth inhibition assay | Inhibition of human HT-1376 cell growth in a cell viability assay, IC50 = 20.5772 μM. | SANGER | |||
| SW982 | Growth inhibition assay | Inhibition of human SW982 cell growth in a cell viability assay, IC50 = 20.6837 μM. | SANGER | |||
| SK-N-FI | Growth inhibition assay | Inhibition of human SK-N-FI cell growth in a cell viability assay, IC50 = 21.0886 μM. | SANGER | |||
| SCC-9 | Growth inhibition assay | Inhibition of human SCC-9 cell growth in a cell viability assay, IC50 = 21.1409 μM. | SANGER | |||
| SW756 | Growth inhibition assay | Inhibition of human SW756 cell growth in a cell viability assay, IC50 = 21.2156 μM. | SANGER | |||
| SW948 | Growth inhibition assay | Inhibition of human SW948 cell growth in a cell viability assay, IC50 = 21.5236 μM. | SANGER | |||
| SW1573 | Growth inhibition assay | Inhibition of human SW1573 cell growth in a cell viability assay, IC50 = 21.8345 μM. | SANGER | |||
| NCI-H1792 | Growth inhibition assay | Inhibition of human NCI-H1792 cell growth in a cell viability assay, IC50 = 21.8565 μM. | SANGER | |||
| BE-13 | Growth inhibition assay | Inhibition of human BE-13 cell growth in a cell viability assay, IC50 = 22.5873 μM. | SANGER | |||
| SK-OV-3 | Growth inhibition assay | Inhibition of human SK-OV-3 cell growth in a cell viability assay, IC50 = 22.7388 μM. | SANGER | |||
| PA-1 | Growth inhibition assay | Inhibition of human PA-1 cell growth in a cell viability assay, IC50 = 22.8712 μM. | SANGER | |||
| NCI-H1693 | Growth inhibition assay | Inhibition of human NCI-H1693 cell growth in a cell viability assay, IC50 = 22.9313 μM. | SANGER | |||
| no-10 | Growth inhibition assay | Inhibition of human no-10 cell growth in a cell viability assay, IC50 = 23.3588 μM. | SANGER | |||
| JVM-2 | Growth inhibition assay | Inhibition of human JVM-2 cell growth in a cell viability assay, IC50 = 23.4147 μM. | SANGER | |||
| SK-NEP-1 | Growth inhibition assay | Inhibition of human SK-NEP-1 cell growth in a cell viability assay, IC50 = 23.5205 μM. | SANGER | |||
| PC-3 | Growth inhibition assay | Inhibition of human PC-3 cell growth in a cell viability assay, IC50 = 23.5722 μM. | SANGER | |||
| U-2-OS | Growth inhibition assay | Inhibition of human U-2-OS cell growth in a cell viability assay, IC50 = 23.8469 μM. | SANGER | |||
| NBsusSR | Growth inhibition assay | Inhibition of human NBsusSR cell growth in a cell viability assay, IC50 = 24.1062 μM. | SANGER | |||
| EW-13 | Growth inhibition assay | Inhibition of human EW-13 cell growth in a cell viability assay, IC50 = 24.1398 μM. | SANGER | |||
| BT-20 | Growth inhibition assay | Inhibition of human BT-20 cell growth in a cell viability assay, IC50 = 24.7178 μM. | SANGER | |||
| MS-1 | Growth inhibition assay | Inhibition of human MS-1 cell growth in a cell viability assay, IC50 = 25.0498 μM. | SANGER | |||
| HCC1187 | Growth inhibition assay | Inhibition of human HCC1187 cell growth in a cell viability assay, IC50 = 25.4451 μM. | SANGER | |||
| TE-1 | Growth inhibition assay | Inhibition of human TE-1 cell growth in a cell viability assay, IC50 = 25.6953 μM. | SANGER | |||
| MKN7 | Growth inhibition assay | Inhibition of human MKN7 cell growth in a cell viability assay, IC50 = 25.7913 μM. | SANGER | |||
| NCI-H727 | Growth inhibition assay | Inhibition of human NCI-H727 cell growth in a cell viability assay, IC50 = 26.0513 μM. | SANGER | |||
| H4 | Growth inhibition assay | Inhibition of human H4 cell growth in a cell viability assay, IC50 = 26.3768 μM. | SANGER | |||
| 647-V | Growth inhibition assay | Inhibition of human 647-V cell growth in a cell viability assay, IC50 = 26.8811 μM. | SANGER | |||
| KM-H2 | Growth inhibition assay | Inhibition of human KM-H2 cell growth in a cell viability assay, IC50 = 26.924 μM. | SANGER | |||
| ABC-1 | Growth inhibition assay | Inhibition of human ABC-1 cell growth in a cell viability assay, IC50 = 27.1974 μM. | SANGER | |||
| HCC1806 | Growth inhibition assay | Inhibition of human HCC1806 cell growth in a cell viability assay, IC50 = 27.3422 μM. | SANGER | |||
| ES5 | Growth inhibition assay | Inhibition of human ES5 cell growth in a cell viability assay, IC50 = 27.4999 μM. | SANGER | |||
| C3A | Growth inhibition assay | Inhibition of human C3A cell growth in a cell viability assay, IC50 = 27.5694 μM. | SANGER | |||
| TE-10 | Growth inhibition assay | Inhibition of human TE-10 cell growth in a cell viability assay, IC50 = 27.6356 μM. | SANGER | |||
| S-117 | Growth inhibition assay | Inhibition of human S-117 cell growth in a cell viability assay, IC50 = 27.7571 μM. | SANGER | |||
| TGBC1TKB | Growth inhibition assay | Inhibition of human TGBC1TKB cell growth in a cell viability assay, IC50 = 27.9902 μM. | SANGER | |||
| NCI-H1793 | Growth inhibition assay | Inhibition of human NCI-H1793 cell growth in a cell viability assay, IC50 = 28.3076 μM. | SANGER | |||
| ES4 | Growth inhibition assay | Inhibition of human ES4 cell growth in a cell viability assay, IC50 = 28.7352 μM. | SANGER | |||
| AN3-CA | Growth inhibition assay | Inhibition of human AN3-CA cell growth in a cell viability assay, IC50 = 28.8593 μM. | SANGER | |||
| NMC-G1 | Growth inhibition assay | Inhibition of human NMC-G1 cell growth in a cell viability assay, IC50 = 29.111 μM. | SANGER | |||
| NCI-H226 | Growth inhibition assay | Inhibition of human NCI-H226 cell growth in a cell viability assay, IC50 = 29.2701 μM. | SANGER | |||
| NCI-H522 | Growth inhibition assay | Inhibition of human NCI-H522 cell growth in a cell viability assay, IC50 = 29.8339 μM. | SANGER | |||
| SW48 | Growth inhibition assay | Inhibition of human SW48 cell growth in a cell viability assay, IC50 = 29.9252 μM. | SANGER | |||
| OE33 | Growth inhibition assay | Inhibition of human OE33 cell growth in a cell viability assay, IC50 = 30.7954 μM. | SANGER | |||
| NCI-H2228 | Growth inhibition assay | Inhibition of human NCI-H2228 cell growth in a cell viability assay, IC50 = 31.0344 μM. | SANGER | |||
| D-423MG | Growth inhibition assay | Inhibition of human D-423MG cell growth in a cell viability assay, IC50 = 31.0564 μM. | SANGER | |||
| IST-MEL1 | Growth inhibition assay | Inhibition of human IST-MEL1 cell growth in a cell viability assay, IC50 = 31.1528 μM. | SANGER | |||
| A388 | Growth inhibition assay | Inhibition of human A388 cell growth in a cell viability assay, IC50 = 31.6236 μM. | SANGER | |||
| LN-405 | Growth inhibition assay | Inhibition of human LN-405 cell growth in a cell viability assay, IC50 = 31.7983 μM. | SANGER | |||
| DMS-273 | Growth inhibition assay | Inhibition of human DMS-273 cell growth in a cell viability assay, IC50 = 31.9138 μM. | SANGER | |||
| KS-1 | Growth inhibition assay | Inhibition of human KS-1 cell growth in a cell viability assay, IC50 = 33.1321 μM. | SANGER | |||
| NCI-H209 | Growth inhibition assay | Inhibition of human NCI-H209 cell growth in a cell viability assay, IC50 = 33.4517 μM. | SANGER | |||
| HOS | Growth inhibition assay | Inhibition of human HOS cell growth in a cell viability assay, IC50 = 33.7253 μM. | SANGER | |||
| GI-1 | Growth inhibition assay | Inhibition of human GI-1 cell growth in a cell viability assay, IC50 = 33.8071 μM. | SANGER | |||
| RERF-LC-MS | Growth inhibition assay | Inhibition of human RERF-LC-MS cell growth in a cell viability assay, IC50 = 34.0315 μM. | SANGER | |||
| NCI-H526 | Growth inhibition assay | Inhibition of human NCI-H526 cell growth in a cell viability assay, IC50 = 34.076 μM. | SANGER | |||
| RPMI-2650 | Growth inhibition assay | Inhibition of human RPMI-2650 cell growth in a cell viability assay, IC50 = 34.4334 μM. | SANGER | |||
| KYSE-70 | Growth inhibition assay | Inhibition of human KYSE-70 cell growth in a cell viability assay, IC50 = 34.8426 μM. | SANGER | |||
| Capan-2 | Growth inhibition assay | Inhibition of human Capan-2 cell growth in a cell viability assay, IC50 = 36.4652 μM. | SANGER | |||
| OVCAR-4 | Growth inhibition assay | Inhibition of human OVCAR-4 cell growth in a cell viability assay, IC50 = 37.2176 μM. | SANGER | |||
| OVCAR-8 | Growth inhibition assay | Inhibition of human OVCAR-8 cell growth in a cell viability assay, IC50 = 37.9823 μM. | SANGER | |||
| NCI-H1355 | Growth inhibition assay | Inhibition of human NCI-H1355 cell growth in a cell viability assay, IC50 = 38.1051 μM. | SANGER | |||
| COLO-680N | Growth inhibition assay | Inhibition of human COLO-680N cell growth in a cell viability assay, IC50 = 38.2429 μM. | SANGER | |||
| NCI-H2122 | Growth inhibition assay | Inhibition of human NCI-H2122 cell growth in a cell viability assay, IC50 = 39.3363 μM. | SANGER | |||
| Saos-2 | Growth inhibition assay | Inhibition of human Saos-2 cell growth in a cell viability assay, IC50 = 39.7053 μM. | SANGER | |||
| HCC2157 | Growth inhibition assay | Inhibition of human HCC2157 cell growth in a cell viability assay, IC50 = 40.7734 μM. | SANGER | |||
| VMRC-RCZ | Growth inhibition assay | Inhibition of human VMRC-RCZ cell growth in a cell viability assay, IC50 = 41.2962 μM. | SANGER | |||
| ETK-1 | Growth inhibition assay | Inhibition of human ETK-1 cell growth in a cell viability assay, IC50 = 41.5751 μM. | SANGER | |||
| RCC10RGB | Growth inhibition assay | Inhibition of human RCC10RGB cell growth in a cell viability assay, IC50 = 42.018 μM. | SANGER | |||
| KP-N-YS | Growth inhibition assay | Inhibition of human KP-N-YS cell growth in a cell viability assay, IC50 = 42.0641 μM. | SANGER | |||
| T98G | Growth inhibition assay | Inhibition of human T98G cell growth in a cell viability assay, IC50 = 42.6733 μM. | SANGER | |||
| A431 | Growth inhibition assay | Inhibition of human A431 cell growth in a cell viability assay, IC50 = 45.1831 μM. | SANGER | |||
| HDLM-2 | Growth inhibition assay | Inhibition of human HDLM-2 cell growth in a cell viability assay, IC50 = 45.2617 μM. | SANGER | |||
| CHP-134 | Growth inhibition assay | Inhibition of human CHP-134 cell growth in a cell viability assay, IC50 = 46.1779 μM. | SANGER | |||
| J-RT3-T3-5 | Growth inhibition assay | Inhibition of human J-RT3-T3-5 cell growth in a cell viability assay, IC50 = 46.4461 μM. | SANGER | |||
| NCI-H1650 | Growth inhibition assay | Inhibition of human NCI-H1650 cell growth in a cell viability assay, IC50 = 46.5104 μM. | SANGER | |||
| MHH-PREB-1 | Growth inhibition assay | Inhibition of human MHH-PREB-1 cell growth in a cell viability assay, IC50 = 46.5266 μM. | SANGER | |||
| SJRH30 | Growth inhibition assay | Inhibition of human SJRH30 cell growth in a cell viability assay, IC50 = 46.7775 μM. | SANGER | |||
| SF295 | Growth inhibition assay | Inhibition of human SF295 cell growth in a cell viability assay, IC50 = 48.519 μM. | SANGER | |||
| YAPC | Growth inhibition assay | Inhibition of human YAPC cell growth in a cell viability assay, IC50 = 48.942 μM. | SANGER | |||
| EFM-19 | Growth inhibition assay | Inhibition of human EFM-19 cell growth in a cell viability assay, IC50 = 49.5085 μM. | SANGER | |||
| MIAPaCa2 | Proliferation assay | Antiproliferative activity against human MIAPaCa2 cells, IC50=142 nM. | 23474388 | |||
| A375 | Proliferation assay | 72 h | Antiproliferative activity against human A375 cells expressing BRAF V600E mutant after 72 hrs by Cell titer-glo assay, IC50=31 nM. | 23474388 | ||
| A549 | Antiproliferative assay | Antiproliferative activity against human A549 cells, IC50 = 1.75 μM. | 23474388 | |||
| LoVo | Antiproliferative assay | Antiproliferative activity against human LoVo cells, IC50 = 2.83 μM. | 23474388 | |||
| HCT116 | Antiproliferative assay | Antiproliferative activity against human HCT116 cells expressing KRAS G13D mutant, IC50 = 3.1 μM. | 23474388 | |||
| HeLa-MaTu | Function assay | Inhibition of MEK1 in human HeLa-MaTu matched pair cells assessed as reduction in ERK phosphorylation, IC50 = 0.014 μM. | 26611920 | |||
| HepG2 | Antiproliferative assay | Antiproliferative activity against human HepG2 cells harboring N-Ras mutation, IC50 = 0.032 μM. | 26611920 | |||
| COLO205 | Antiproliferative assay | Antiproliferative activity against human COLO205 cells harboring BRAF mutation, IC50 = 0.069 μM. | 26611920 | |||
| A549 | Antiproliferative assay | Antiproliferative activity against human A549 cells harboring K-Ras mutation, IC50 = 1.75 μM. | 26611920 | |||
| HCT116 | Antiproliferative assay | Antiproliferative activity against human HCT116 cells harboring K-Ras G13D mutation, IC50 = 3 μM. | 26611920 | |||
| HeLa-MaTu-ADR | Function assay | Inhibition of MEK1 in human HeLa-MaTu-ADR matched pair cells assessed as reduction in ERK phosphorylation, IC50 = 3.7 μM. | 26611920 | |||
| SW480 | Antiproliferative assay | 72 hrs | Antiproliferative activity against human SW480 cells after 72 hrs by MTT assay, IC50 = 0.422 μM. | 27448918 | ||
| SW620 | Antiproliferative assay | 72 hrs | Antiproliferative activity against human SW620 cells harboring KRAS G12V mutant after 72 hrs by CellTiter-Glo assay, IC50 = 0.015 μM. | 28038940 | ||
| AsPC1 | Antiproliferative assay | 72 hrs | Antiproliferative activity against human AsPC1 cells harboring KRAS G12D mutant after 72 hrs by CellTiter-Glo assay, IC50 = 0.0642 μM. | 28038940 | ||
| BA/F3 | Antiproliferative assay | 72 hrs | Antiproliferative activity against mouse BA/F3 cells harboring KRAS G12D mutant after 72 hrs by CellTiter-Glo assay, IC50 = 0.1 μM. | 28038940 | ||
| SKCO1 | Antiproliferative assay | 72 hrs | Antiproliferative activity against human SKCO1 cells harboring KRAS G12V mutant after 72 hrs by CellTiter-Glo assay, IC50 = 0.117 μM. | 28038940 | ||
| COLO205 | Antiproliferative assay | 72 hrs | Antiproliferative activity against human COLO205 cells harboring BRAF mutant/wild type KRAS/wild type PIK3CA after 72 hrs by CCK8 assay, IC50 = 0.059 μM. | 29317148 | ||
| Klicken Sie hier, um weitere experimentelle Daten zu Zelllinien anzuzeigen | ||||||
Chemische Informationen, Lagerung & Stabilität
| Molekulargewicht | 457.68 | Formel | C17H15BrClFN4O3 |
Lagerung (Ab dem Eingangsdatum) | |
|---|---|---|---|---|---|
| CAS-Nr. | 606143-52-6 | SDF herunterladen | Lagerung von Stammlösungen |
|
|
| Synonyme | ARRY-142886 | Smiles | CN1C=NC2=C1C=C(C(=C2F)NC3=C(C=C(C=C3)Br)Cl)C(=O)NOCCO | ||
Löslichkeit
|
In vitro |
DMSO
: 91 mg/mL
(198.82 mM)
Water : Insoluble Ethanol : Insoluble |
Molaritätsrechner
Verdünnungsrechner
Molekulargewichtsrechner
|
In vivo |
|||||
In-vivo-Formulierungsrechner (Klare Lösung)
Schritt 1: Geben Sie die untenstehenden Informationen ein (Empfohlen: Ein zusätzliches Tier zur Berücksichtigung von Verlusten während des Experiments)
mg/kg
g
μL
Schritt 2: Geben Sie die In-vivo-Formulierung ein (Dies ist nur der Rechner, keine Formulierung. Bitte kontaktieren Sie uns zuerst, wenn es im Abschnitt "Löslichkeit" keine In-vivo-Formulierung gibt.)
% DMSO
%
% Tween 80
% ddH2O
%DMSO
%
Berechnungsergebnisse:
Arbeitskonzentration: mg/ml;
Methode zur Herstellung der DMSO-Stammlösung: mg Wirkstoff vorgelöst in μL DMSO ( Konzentration der Stammlösung mg/mL, Bitte kontaktieren Sie uns zuerst, wenn die Konzentration die DMSO-Löslichkeit der Wirkstoffcharge überschreitet. )
Methode zur Herstellung der In-vivo-Formulierung: Nehmen Sie μL DMSO Stammlösung, dann hinzufügenμL PEG300, mischen und klären, dann hinzufügenμL Tween 80, mischen und klären, dann hinzufügen μL ddH2O, mischen und klären.
Methode zur Herstellung der In-vivo-Formulierung: Nehmen Sie μL DMSO Stammlösung, dann hinzufügen μL Maisöl, mischen und klären.
Hinweis: 1. Bitte stellen Sie sicher, dass die Flüssigkeit klar ist, bevor Sie das nächste Lösungsmittel hinzufügen.
2. Achten Sie darauf, das/die Lösungsmittel der Reihe nach hinzuzufügen. Sie müssen sicherstellen, dass die bei der vorherigen Zugabe erhaltene Lösung eine klare Lösung ist, bevor Sie mit der Zugabe des nächsten Lösungsmittels fortfahren. Physikalische Methoden wie Vortex, Ultraschall oder ein heißes Wasserbad können zur Unterstützung des Lösens verwendet werden.
Wirkmechanismus
| Merkmale |
First MEK inhibitor being tested in Phase II clinical trials.
|
|---|---|
| Targets/IC50/Ki |
MEK1
(Cell-free assay) 14 nM
MEK1
(Cell-free assay) 99 nM(Kd)
MEK2
(Cell-free assay) 530 nM(Kd)
|
| In vitro |
Selumetinib (AZD6244) ist nicht kompetitiv mit ATP und inaktiviert die ERK1/2-Phosphorylierung mit IC50-Konzentrationen unter 40 nM. Es hemmt auch das Wachstum primärer HCC-Zellen durch Hemmung der ERK1/2- und p90RSK-Phosphorylierung, begleitet von einer Erhöhung der Spaltung von Caspase-3 und Caspase-7 sowie gespaltener Poly(ADP)ribose-Polymerase. Diese Verbindung hat geringe Auswirkungen auf die p38-, c-Jun-NH2-Kinase-, Phosphatidylinositol-3-Kinase- und MEK5/ERK5-Signalwege. Es ist empfindlich gegenüber Raf-Mutationen in Brustkrebszelllinien und Ras-Mutationen in NSCLC-Zelllinien. |
| Kinase-Assay |
Assay der MEK-Kinase-Aktivität
|
|
Selumetinib (AZD6244) wird verwendet, um MEK1-Moleküle zu immunpräzipitieren. Die MEK-Kinase-Aktivität wird als die Fähigkeit von immun-isoliertem MEK1 gemessen, rekombinante ERK1 in einem gekoppelten Assay zu aktivieren, wobei MBP als Endpunkt des Assays dient. Phosphoryliertes MBP wird auf einem 14%igen SDS-PAGE-Gel getrennt und vakuumgetrocknet, bevor es einem Röntgenfilm ausgesetzt wird.
|
|
| In vivo |
Selumetinib (AZD6244) hemmt signifikant die Phosphorylierung von ERK1/2 in 2-1318-, 5-1318-, 26-1004- und 4-1318-Xenografts und induziert Apoptose in primären 2-1318-Zellen durch Aktivierung des Caspase-Signalwegs. Es könnte das Tumorwachstum in HT-29-Xenografts, einem Darmkrebsmodell mit einer B-Raf-Mutation, bei einer Dosis von 100 mg/kg hemmen, und die Tumorwachstumshemmung dieser Verbindung ist besser. Andernfalls könnte es das Tumorwachstum von HCC-Xenografts hemmen, was mit erhöhter Apoptose und Herunterregulierung von Zellzyklusregulatoren, einschließlich Cyclin D1, Cdc-2, CDK2 und 4, Cyclin B1 und c-Myc, verbunden ist. |
Literatur |
|
Anwendungen
| Methoden | Biomarker | Bilder | PMID |
|---|---|---|---|
| Western blot | p-ERK / ERK / β-catenin / E-cadherin / Vimentin / Fibronection pS6(235/236) / pS6(240/244) pVEGFR(Y1175) / VEGFR2 / pPDGFRβ(Y751) / pPDGFRβ / pAXL(Y702) / AXL / pMEK / MEK Bak / Bad / Bcl-xl / BimEL / BimL / BimS / PUMA / NOXA |
|
26384399 |
| Immunofluorescence | β-catenin FOXO3a |
|
26384399 |
| Growth inhibition assay | Cell viability |
|
26384399 |
Klinische Studieninformationen
(Daten von https://clinicaltrials.gov, aktualisiert am 2024-05-22)
| NCT-Nummer | Rekrutierung | Erkrankungen | Sponsor/Kooperationspartner | Startdatum | Phasen |
|---|---|---|---|---|---|
| NCT05253131 | Not yet recruiting | MPNST|NF1|Sarcoma |
University of Alabama at Birmingham|United States Department of Defense |
June 15 2024 | Phase 2 |
| NCT06175637 | Recruiting | Neurofibroma Plexiform |
AstraZeneca |
December 20 2023 | -- |
| NCT05891847 | Recruiting | Neurofibroma |
AstraZeneca |
March 21 2023 | -- |
| NCT05101148 | Active not recruiting | Neurofibromatosis Type 1 |
AstraZeneca|Merck Sharp & Dohme LLC |
July 21 2021 | Phase 1 |
| NCT04879160 | Completed | Neurofibromatosis 1 |
National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) |
May 12 2021 | -- |
Technischer Support
Tel: +1-832-582-8158 Ext:3
Wenn Sie weitere Fragen haben, hinterlassen Sie bitte eine Nachricht.
Häufig gestellte Fragen
Frage 1:
How about the solubility of it? How to prepare for the solution if I need to do the in vivo experiments?
Antwort:
It will be a suspension for oral administration in vehicle 5% DMSO+30% PEG 300+ddH2O. If you want a clear solution for injection, you can dissolve it in 4% DMSO+30% PEG 300+5% Tween 80+ddH2O.
Produkte sind nur für Forschungszwecke bestimmt. Nicht für den menschlichen Gebrauch. Wir verkaufen nicht an Patienten.
©Copyright 2013 Selleck Chemicals. Alle Rechte vorbehalten.